Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

87 results about "Pyridoxamine" patented technology

Pyridoxamine is one form of vitamin B₆. Chemically it is based on a pyridine ring structure, with hydroxyl, methyl, aminomethyl, and hydroxymethyl substituents. It differs from pyridoxine by the substituent at the 4-position. The phenol at position 3 and aminomethyl group at position 4 of its ring endow pyridoxamine with a variety of chemical properties, including the scavenging of free radical species and carbonyl species formed in sugar and lipid degradation and chelation of metal ions that catalyze Amadori reactions.

Topical compositions comprising benfotiamine and pyridoxamine

InactiveUS20060045896A1Inhibition formationPrevention and treatment of damageBiocideOrganic active ingredientsHypopigmentationWrinkle skin
The present invention provides a composition comprising an effective amount of benfotiamine and an effective amount of pyridoxamine in a suitable vehicle for topical application. The present compositions are useful in improving the appearance of aged skin characterized by wrinkles, loss of elasticity, and hyperpigmentation caused by chronoaging and / or photoaging of skin, by inhibiting particularly skin damage resulting from reactive carbonyl species (RCS), glycation of skin proteins, formation of advanced glycation endproducts (AGEs) and formation of advanced lipoxidation endproducts (ALEs).
Owner:TRACIE MARTYN INT

Treatment of cerebrovascular disease

A method of treating a cerebrovascular disease, particularly stroke, is described. A method of treating a cerebrovascular disease includes administering pyridoxal-5′-phosphate, pyridoxal, pyridoxine, pyridoxamine, 3-acylated analogues of pyridoxal, 3-acylated analogues of pyridoxal-4,5-aminal, pyridoxine phosphonate analogues, or pharmaceutical compositions thereof.
Owner:MEDICURE INT INC

Compounds and methods for regulating triglyceride levels

InactiveUS20060148763A1Treating and preventing hypertriglyceridemiaBiocideOrganic chemistryLipid formationHMG-CoA reductase
The present invention provides a method of administering vitamin B6 related compounds for treatment of hypertriglyceridemia. Vitamin B6 related compounds include pyridoxal, pyridoxal-5′-phosphate, pyridoxamine, a 3-acylated analogue of pyridoxal, a 3-acylated analogue of pyridoxal-4,5-aminal, and mixtures thereof. Embodiments of the present invention also comprise co-administering a lipid lowering agent, such as a nicotinic acid, a fibrate, a HMG CoA reductase inhibitor, a cholesteryl ester transfer protein inhibitor, and combinations thereof.
Owner:MEDICURE INT INC

Compositions for treating angina

A method of treating angina in a mammal includes administering pyridoxal-5′-phosphate, pyridoxal, pyridoxine, pyridoxamine, 3-acylated analogues of pyridoxal, 3-acylated analogues of pyridoxal-4,5-aminal, pyridoxine phosphonate analogues, or pharmaceutical compositions thereof.
Owner:MEDICURE INT INC

Treatment of cerebrovascular disease

A method of treating a cerebrovascular disease, particularly stroke, is described. A method of treating a cerebrovascular disease includes administering pyridoxal-5'-phosphate, pyridoxal, pyridoxine, pyridoxamine, 3-acylated analogues of pyridoxal, 3-acylated analogues of pyriodoxal-4,5-animal, pyridoxine phosphonate analogues, or pharmaceutical compositions thereof.
Owner:MEDICURE INT INC

Modulation of cell death

A method of modulating cell death includes administering pyridoxal-5′phosphate, pyridoxal, pyridoxine, pyridoxamine, 3-acylated analogues of pyridoxal, 3-acylated analogues of pyridoxal-4,5-aminal, pyridoxine phosphonate analogues, or pharmaceutical compositions thereof.
Owner:MEDICURE

Treatment of cardiovascular and related pathologies

Methods for treating cardiovascular and related diseases such as ischemia, ischemia reperfusion injuries, and myocardial ischemia, are described. The methods are directed to concurrently administering a compound such as pyridoxal-5′-phosphate, pyridoxamine, pyridoxal, or a 3-acylated pyridoxal analogue with a therapeutic cardiovascular compound.
Owner:MEDICURE INT INC

Treatment of cardiovascular and related pathologies

Methods for treating cardiovascular and related diseases such congestive heart failure are described. The methods are directed to concurrently administering a compound such as pyridoxal-5′-phosphate, pyridoxamine, pyridoxal, or a 3-acylated pyridoxal analogue with a therapeutic cardiovascular compound.
Owner:MEDICURE INT INC

Pyridoxamine for the treatment of diabetic kidney disease

The present invention provides pharmaceutical compositions comprising dosage units of pyridoxamine, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier, and methods for their use in limiting the progression of renal disease and / or diabetic complications in human diabetic patient.
Owner:NEPHROGENEX

Method of preventing and/or treating oxidant injury in neurodegenerative and oxidative diseases

A method of treating and / or preventing oxidative damage, comprising administering an effective IsoK / NeuroK adduct formation suppressing amount of a phenolic amine compound and / or pyridoxamine or pyridoxamine analog, including embodiments where the phenolic compound is at least one of a pyridoxamine, salicylamine, tyrosine compound or an analog thereof.
Owner:VANDERBILT UNIV

Isoketal scavengers and mitigation of disorders involving oxidative injury

ActiveUS20120157501A1Reduction in choline acetyltransferase activityReduced activityBiocideNervous disorderScavengerMedicine
A method of treating and / or preventing oxidative damage, comprising administering an effective IsoK / NeuroK adduct formation suppressing amount of a phenolic amine compound and / or pyridoxamine or pyridoxamine analog, including embodiments where the phenolic compound is at least one of a pyridoxamine, salicylamine, tyrosine compound or an analog thereof.
Owner:VANDERBILT UNIV

Treatment of atrial fibrillation

InactiveUS20070249562A1BiocideAnimal repellantsPyridoxic AcidPhosphate
The invention includes a method of treating atrial fibrillation in a mammal that includes administering a therapeutically effective amount of at least one therapeutic compound Compounds suitable for use in the methods of the invention include pyridoxal-5′-phosphate, pyridoxic acid, pyridoxamine, pyridoxal, 3-acylated pyridoxal analogues, pharmaceutically acceptable acid addition salts thereof, and mixtures thereof.
Owner:MEDICURE INT INC

Health care beverage for eyesight

The present invention relates to a beverage, in particular, it relates to a health-care beverage capable of protecting and raising visual acuity. The raw material composition of said health-care beverage includes the following several components: white granulated sugar, peach juice, carrot juice, tomato pulp, citric acid, sorbic acid, xanthophylls, vitamin B1, vitamin B2, vitamin C, beta-carrotene, pyridoxamine, carboxymethyl cellulose, pectin and pure water. Said invention also provides its preparation method and concrete operation steps.
Owner:SHANDONG MINGMU BIOTECH

Methods For Diagnosing And Treating Diabetic Microvascular Complications

InactiveUS20080096923A1Effective treatmentBiocideSenses disorderEnzastaurinPegaptanib
The present invention relates to a method for treating one or more diabetic microvascular complications in a patient in need of said treatment comprising: (a) diagnosing the severity of at least three different microvascular complications in said patient by calculating a diabetes microvascular complications score with a diabetes microvascular complications scoring tool; and (b) administering to said patient in need thereof a therapeutic amount of a compound selected from the group consisting of ruboxistaurin, enzastaurin, PKC 412, candesartan cilexetil, fidarestat, lidorestat, pyridoxamine and pegaptanib, or a pharmaceutically acceptable salt thereof, and ranibizumab; in an amount that is effective in treating one or more diabetic microvascular complications in said diabetic patient.
Owner:ELI LILLY & CO

Medicine used for preventing and treating cardiovascular disease

The invention discloses a medicine for treating cardiovascular disease. The medicine comprises the following components: 25-40 parts of herbal powder, 5-10 parts of ginkgo biloba extract, 5-10 parts of erigeron breviscapus powder, 0.2-0.5 part of a nitric oxide production accelerant, and 0.5-1 part of a platelet aggregation reducing agent. The raw materials are uniformly mixed according to the proportion, so as to obtain the medicine. The nitric oxide production accelerant is a mixture of arginine, citrulline and folic acid; the platelet aggregation reducing agent is any one of pyridoxine, pyridoxal and pyridoxamine; the herbal powder comprises the following components: 15-20 parts of radix puerariae, 15-20 parts of astragalus membranaceus, 10-15 parts of cyperus rotundus, 5-10 parts of radix curcumae, 5-10 parts of trichosanthes kirilowii, 3-5 parts of pinellia ternata, 3-5 parts of scutellaria baicalensis, 1-3 parts of schisandra chinensis, 2-4 parts of glossy privet fruit, 3-6 parts of fruit of Chinese wolfberry, 1-3 parts of semen cuscutae, 2-5 parts of herba epimedii and 1-3 parts of fructus psoraleae. The medicine provided by the invention has quick curative effect on cardiovascular disease, is short in treatment course, has good curative effect on the cardiovascular disease, and has a certain protection function on spleen, stomach and liver.
Owner:THE AFFILIATED HOSPITAL OF QINGDAO UNIV

Novel chiral open-chain pyridoxamine catalyst and synthesis method and application thereof

The invention relates to a novel chiral open-chain pyridoxamine catalyst and a synthesis method and application thereof. The structural general formula of the pyridoxamine catalyst is shown in the specification, wherein R1, R2, R3 and R4 are one of hydrogen, C1-24 alkyl, C1-24 alkyl containing substituent groups, substances shown in the specification and halogen, the substituent groups on C1-24 alkyl are a substance shown in the specification or a substance shown in the specification or a substance shown in the specification or O-Rw or S-Rw' or halogen, and Rx, Rx', Ry, Ry', Ry'', Rz, Rz', Rw and Rw' are one of hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, tertiary butyl, cyclopentyl, cyclohexyl, cycloheptyl, phenyl, benzyl, (1-phenyl)ethyl, 1-naphthyl, 2-naphthyl and halogen. Compared with the prior art, the pyridoxamine catalyst can achieve rapid and efficient synthesis of chiral amino acid, the preparation raw materials are easy to obtain, reaction conditions are mild, cost is low, and when the novel chiral open-chain pyridoxamine catalyst is used for a transamination reaction, the conditions are mild, and the reaction is stable.
Owner:SHANGHAI NORMAL UNIVERSITY

Methods for the synthesis of pyridoxamine

The invention provides non-oxidative methods for the large scale manufacture of pyridoxamine (I) (4-aminomethyl-3-hydroxy-5-hydroxymethyl-2-methylpyridine): The invention also provides intermediate compounds for the synthesis of pyridoxamine, as well as compositions and methods for the treatment and / or prevention of conditions associated with the formation of post-Amadori advanced glycation end-products.
Owner:PRAETEGO INC

Treatment of cerebrovascular disease

A method of treating a cerebrovascular disease, particularly stroke, is described. A method of treating a cerebrovascular disease includes administering pyridoxal-5'-phosphate, pyridoxal, pyridoxine, pyridoxamine, 3-acylated analogues of pyridoxal, 3-acylated analogues of pyridoxal-4,5-aminal, pyridoxine phosphonate analogues, or pharmaceutical compositions thereof.
Owner:MEDICURE INT INC

Beverage mixer formulation

Formulations for producing alcohol-containing beverages may be provided in single serving packages and combined with liquid at a point of use. An exemplary beverage mixer includes a flavoring agent, L-glutamine, ginger root, and at least two of the following items (i) to (v): (i) thiamine; (ii) pantothenic acid; (iii) pyridoxine, pyridoxal, or pyridoxamine; (iv) cobalmin; and (v) folic acid. Particulate-based and tablet-based solid forms and liquid forms are disclosed.
Owner:BUTABI BROS

Feed additive for enhancing immunity of yellow catfish

The invention relates to a feed additive for enhancing immunity of yellow catfish, which is prepared from, by weight, 5-8 parts of L-lysine, 1-3 parts of magnesium acetate, 1-3 parts of organic selenium, 1-3 parts of trehalose, 2-5 parts of taurine, 5-8 parts of calcium pantothenate, 8-12 parts of creatine monohydrate, 5-8 parts of L-citrulline, 3-6 parts of sodium propionate, 2-5 parts of zinc gluconate, 5-8 parts of calcium hydrophosphate, 3-6 parts of calcium glycinate, 3-6 parts of pyridoxamine, 2-5 parts of folic acid, 2-5 parts of choline chloride, 5-8 parts of betaine, 2-4 parts of dimethyl-beta-propiothetin, 2-5 parts of sodium chloride, 2-5 parts of inositol, 1-3 parts of vitamin A, 1-3 parts of vitamin B, 5-8 parts of vitamin C, and 2-5 parts of vitamin E. The feed additive can effectively improve the diseases prevention and resistance effect of the yellow catfish and can enhance immunity.
Owner:CHANGSHA RUIDUOKANG BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products